Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):9-15. doi: 10.1007/s00259-019-04529-8.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adenocarcinoma / diagnostic imaging*
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / secondary
  • Androgen Antagonists / pharmacology*
  • Androgen Antagonists / therapeutic use
  • Androgens*
  • Antigens, Neoplasm / analysis
  • Antigens, Neoplasm / biosynthesis*
  • Antigens, Surface / analysis
  • Antigens, Surface / biosynthesis*
  • Antineoplastic Agents, Hormonal / pharmacology*
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Bone Neoplasms / diagnostic imaging
  • Bone Neoplasms / secondary
  • Clinical Trials as Topic
  • Gene Expression Regulation, Neoplastic / drug effects
  • Glutamate Carboxypeptidase II / analysis
  • Glutamate Carboxypeptidase II / biosynthesis*
  • Gonadotropin-Releasing Hormone / agonists
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors
  • Humans
  • Ligands
  • Male
  • Neoplasms, Hormone-Dependent / diagnostic imaging*
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / metabolism
  • Orchiectomy*
  • Positron-Emission Tomography / methods*
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms, Castration-Resistant / diagnostic imaging
  • Prostatic Neoplasms, Castration-Resistant / metabolism
  • Receptors, Androgen / drug effects
  • Receptors, Androgen / physiology

Substances

  • Androgen Antagonists
  • Androgens
  • Antigens, Neoplasm
  • Antigens, Surface
  • Antineoplastic Agents, Hormonal
  • Ligands
  • Receptors, Androgen
  • Gonadotropin-Releasing Hormone
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II